Alle Storys
Folgen
Keine Story von Oxygen Biotherapeutics Inc. mehr verpassen.

Oxygen Biotherapeutics Inc.

EANS-Adhoc: Oxygen Biotherapeutics Enters into Purchase Agreement to Sell $5 million of Unsecured Promissory Notes to Vatea Fund

  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
Biotechnology
13.10.2010
DURHAM, NC, September 13, 2010 - Oxygen Biotherapeutics, Inc. (NASDAQ
& SIX Swiss Exchange: OXBT) Dr. Antoine Carlisle entered into a Note 
Purchase Agreement with JP SPC 1 Vatea, Segregated Portfolio whereby 
the Company agreed to issue and sell to the Vatea an aggregate of  $5
million of senior unsecured promissory notes in a series of closings 
between October 31, 2010, and December 31, 2010.  Vatea is a party to
a securities purchase agreement with the Company, dated June 8, 2009,
and subsequently amended.  Vatea is the Company´s largest 
shareholder, holding approximately 13.68% of the Company´s 
outstanding common stock.  In addition, Gregory Pepin, a director of 
the Company, is Investment Manager to the Vatea Fund.
"We are pleased to provide financial resources to Oxygen 
Biotherapeutics because we believe the Company is well positioned to 
move its commercial and research programs forward," said Mr. Pepin. 
"As a long term investor, we thought it was natural to step in and 
provide the financial support to help the company generate revenue 
from its Dermacyte skin care products and advance its research 
projects."
"We feel privileged to have the Vatea Fund as a long-term investor.  
This financing demonstrates their belief in our strategy and 
represents the catalyst required to enable us to advance on our 
commercial roadmap," said Chris Stern, Chairman & Chief Executive 
Officer of Oxygen Biotherapeutics.
Additional information regarding this agreement well be available on 
Form 8-K filed with the Securities and Exchange Commission at 
www.sec.gov.later today.
end of ad-hoc-announcement ==========================================
====================================== About Oxygen Biotherapeutics, 
Inc. Oxygen Biotherapeutics, Inc. is developing medical and cosmetic 
products that efficiently deliver oxygen to tissues in the body. The 
company has developed a proprietary perfluorocarbon (PFC) therapeutic
oxygen carrier and liquid ventilation product called Oxycyte that is 
being formulated for both intravenous and topical delivery. This 
year, the company launched its DERMACYTE® line of oxygen-rich skin 
care products. In addition, the company is focused on 
perfluorocarbon-based oxygen carriers for use in traumatic brain 
injury, decompression sickness, personal care, and topical wound 
healing. More information is available at www.oxybiomed.com or 
www.buydermacyte.com
Caution Regarding Forward-Looking Statements This news release 
contains certain forward-looking statements by the company that 
involve risks and uncertainties and reflect the company's judgment as
of the date of this release. These statements include the expansion 
of research and development of the Oxycyte product line, including 
Wundecyte, and the timing of the introduction of those new products. 
The forward-looking statements are subject to a number of risks and 
uncertainties including matters beyond the company’s control that 
could lead to delays in new product introductions and customer 
acceptance of these new products, and other risks and uncertainties 
as described in our filings with the Securities and Exchange 
Commission, including in the current report on Form 10-Q filed on 
September 9, 2010. The company disclaims any intent or obligation to 
update these forward-looking statements beyond the date of this 
release. This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
end of announcement                               euro adhoc

Further inquiry note:

Ellen Corliss
Vice President, Corporate Communications
& Investor Relations
Oxygen Biotherapeutics, Inc
2530 Meridian Pkwy, 3rd floor
Durham, NC 27713
Direct Telephone: +1 919 855 2112
Direct Fax: +1 919 806 4417
Email: e.corliss@oxybiomed.com

Branche: Biotechnology
ISIN: US69207P2092
WKN: 10728277
Index: SSIRT
Börsen: New York / Nasdaq
SIX Swiss Exchange / Main Standard

Weitere Storys: Oxygen Biotherapeutics Inc.
Weitere Storys: Oxygen Biotherapeutics Inc.